GH-axis research
CJC-1295 No DAC / Ipamorelin
Peptide lyophilisé de recherche de signalisation endocrinienne pour l'examen des systèmes
CJC-1295 No DAC / Ipamorelin pairs a shorter-exposure GHRH analog with a selective ghrelin receptor secretagogue in one GH-axis research format.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesPour la recherche en laboratoire uniquement. Pas pour un usage humain ou vétérinaire. Non destiné à diagnostiquer, traiter, guérir, atténuer ou prévenir une maladie.
Conserver scellé, froid, sec et protégé des variations de chaleur. Confirmez le stockage spécifique au produit à l'arrivée.
Emballé pour la stabilité du transit avec une assistance aux commandes disponible pour les itinéraires par temps chaud.
Batch-linked certificate support is available through the documentation desk.
Contexte de recherche
Profil de recherche CJC-1295 No DAC / Ipamorelin
CJC-1295 No DAC / Ipamorelin combines two distinct GH-axis research approaches. The CJC component in this listing is the No DAC form: a shorter-exposure GHRH analog that acts at the GHRH receptor, not the DAC-modified albumin-binding version. Ipamorelin is a ghrelin-receptor secretagogue studied at GHS-R. Research commonly examines how these complementary upstream signals affect GH-release patterns, IGF-1 markers, receptor selectivity, pharmacokinetics, or endocrine feedback differently from either component alone. Component studies provide useful context but do not establish the behavior or synergy of a combined catalog product.
Molecular class
Two-peptide GH-axis combination
Sequence / composition
CJC-1295 No DAC, a modified GHRH analog without a Drug Affinity Complex, paired with the five-residue ghrelin-receptor secretagogue ipamorelin; it is not a single sequence.
Research design note
The No-DAC CJC form and component ratio are defined features of this listing when comparing upstream GHRH-receptor and GHS-R signaling.
Mécanisme proposé
Combines shorter-exposure GHRH-receptor agonism from the CJC-1295 No DAC component with GHS-R1a agonism from ipamorelin. Both converge on pituitary growth-hormone release through different upstream receptors, creating a proposed complementary secretagogue model.
Effets rapportés dans les études
- No-DAC GHRH-analog studies examine acute pituitary response, pulse timing, and GH or IGF-1-related markers under the conditions tested.
- Ipamorelin studies reported dose-related GH release with a selectivity profile different from older GHRP compounds.
- The combination itself lacks strong independent evidence demonstrating synergy, a predictable pulse pattern, or improved outcomes over the separate components.
Critères de recherche courants
CJC No DAC identity, GHRH receptor response, GHS-R response, GH pulse amplitude and duration, IGF-1, ACTH, cortisol, prolactin, pharmacokinetics, and component controls.
Preuves et limites
The literature must be matched to the specified No-DAC CJC component and ipamorelin. Blend-specific effects and equivalence to individual study materials are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.